Screening
US guidelines do not recommend screening for malignant pleural mesothelioma because it has not been shown to reduce mortality.[2]
European guidelines conclude that the role of screening in persons exposed to asbestos for early malignant pleural mesothelioma is uncertain.[45] In the absence of family history consistent with BAP1 tumor predisposition syndrome, screening of BAP1-deficient mesothelioma patients for germline mutation is not recommended.[45]
UK guidelines recommend that biomarker testing should not be offered for screening malignant pleural mesothelioma.[44]
Use of this content is subject to our disclaimer